- Land: Schweiz
Nachricht vom 30.08.2018 | 14:00
EBD Group: Global life sciences to convene in Copenhagen for Europe's largest annual biopharma partnering conference
DGAP-News: EBD Group / Key word(s): Conference
Global life sciences to convene in Copenhagen for Europe's largest annual biopharma partnering conference
Carlsbad, CA and Copenhagen, Denmark - August 30, 2018: The 24th annual BIO-EUROPE (R) 2018 Global Life Science Partnership event will be held November 5-7, 2018, in Copenhagen, Denmark, part of Medicon Valley, the leading Scandinavia's life science cluster, supported by regional hosts Copenhagen Capacity, Invest in Skane, LEO Pharma, Lundbeck Fonden, Novo Holdings, Novo Nordisk and Novozymes. 2,200+ life science companies spanning an estimated 60+ countries to engage in one-to-one partnering.
Søren Bregenholt, chairman of the Danish-Swedish life science cluster organization, Medicon. "This is the first time that Europe's largest biotech conference wants to visit Scandinavia, and as a life science professional Valley Alliance. Copenhagen, and Medicon Valley, an exciting and rewarding place to visit, explore and do business. "
BIO-Europe to Copenhagen for the first time, said Anna Chrisman , Group Managing Director, EBD Group. "We are pleased to welcome you to this world-renowned group of Medicon Valley companies . "This biopharma cluster is one of Europe's leading life sciences hubs, with 23 life science parks and incubators, over 350 biotech, medtech and pharmaceutical companies, and groundbreaking research in unmet medical needs, making it the perfect setting for the deal making and discovery that takes place at BIO-Europe to further global drug development. "
BIO-Europe is a "must-attend" event for executives from the global biotechnology industry. Who wants to gain direct access to service and manufacturing partners, innovative assets, and ideas from biotech companies ranging from very early stage to large, established companies. The event is also a critical business strategy for biotech companies to meet with pharmaceutical executives and investors to propel their drug development commercialization goals.
BIO-Europe 2017 broke records for number of delegates and number of one-to-one partnering meetings which reached an all-time high of 24,200, powered by EBD's industry-leading platform, partneringONE. CEOs and decision makers from 2,199 companies discussed asset deals and strategic collaborations. There were 5,142 licensing opportunities on offer, 152 company presentations and 106 exhibitors.
Register for BIO-Europe 2018 before August 31, 2018 , and save EUR 200 off the regular registration rate.
For news and interviews with executives and thought leaders in the life sciences industry, go to EBD Group's Partnering Insight .
# # #
Additional links and information:
Follow BIO-Europe 2018 on Twitter: @EBDGroup (hashtag: #BIOEUROPE).
About EBD Group
EBD Group's overriding mission is to help collaborations across the life science value chain. Our range of partnering conferences has grown to become the largest and most productive conference platform in the industry. Each one of our landmark events is delivered through our state-of-the-art partnering software, partneringONE (R) , that enables delegates to efficiently identify and engage with new opportunities via one-to-one one meetings.
Today our events (BIO-Europe (R), BIO-Europe Spring (R), BioPharm America (TM), Biotech Showcase (TM), BioEquity Europe, ChinaBio (R) Partnering Forum, Cell & Gene Connect, and Digital Medicine & Medtech showcase) attract more than 15,000 senior life science executives who engage in over 50,000 one-to-one partnering meetings. These vital one-to-one engagements are the wellspring of deals that drive innovation in our industry.
Kari Bennett, EBD Group: +1 760 930 0500; email@example.com
European media support
Anne Hennecke, MC Services AG: +49 211 529 252 22; firstname.lastname@example.org
EBD Group: BIO-Europe Spring(R) 2019 comes to ...
BIO-Europe Spring(R) comes to Vienna for Europ ...
Copenhagen welcomed over 4,200 life science ex ...
EBD Group: BIO-Europe(R) 2018 to bring 4,000 l ...
EBD Group: Global life sciences to convene in ...
SBF AG: Die Zeichen für profitables Wachstum stehen auf Grün!
Die SBF AG agiert als Spezialist für Deckensysteme für Schienenfahrzeuge. Die Bahntechnikindustrie gilt als nachhaltiger Wachstumsbereich. Vor dem Hintergrund der starken Positionierung, des eingeschlagenen Wachstumskurses sowie der erwarteten verstärkten Investitionen in den Bahntechniksektor haben wir für die Aktie einen fairen Wert von 3,62 EUR ermittelt. Wir stufen den Titel aufgrund des großen Kurspotenzials mit „Kaufen“ ein.
Der AKTIONÄR News
20. März 15:57 Bayer-Fiasko und Auto-Crash – DAX stürzt ab
20. März 15:54 Gold-Highflyer Franco-Nevada: Kaufchance?
News im Fokus
Fresenius Medical Care ernennt Dr. Frank Maddux zum Chief Medical Officer
20. März 2019, 13:04
20. März 2019
Original-Research: GBC Insider Focus Index (von GBC AG): GBC Insider Focus Index
20. März 2019